GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kite Pharma Inc (NAS:KITE) » Definitions » 3-Year EPS without NRI Growth Rate

Kite Pharma (Kite Pharma) 3-Year EPS without NRI Growth Rate : 0.00% (As of Jun. 2017)


View and export this data going back to 2014. Start your Free Trial

What is Kite Pharma 3-Year EPS without NRI Growth Rate?

Kite Pharma's EPS without NRI for the three months ended in Jun. 2017 was $-1.94.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Competitive Comparison of Kite Pharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Kite Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kite Pharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kite Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Kite Pharma's 3-Year EPS without NRI Growth Rate falls into.



Kite Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Kite Pharma  (NAS:KITE) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Kite Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Kite Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kite Pharma (Kite Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.
Executives
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David Bonderman director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Shawn Tomasello officer: Chief Commercial Officer C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Farah Champsi director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Helen Susan Kim officer: EVP, Business Development 3832 BAY CENTER PLACE, HAYWARD CA 94545
Timothy L. Moore officer: EVP, Technical Operations C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Cynthia M Butitta officer: Chief Operating Officer 3165 PORTER DRIVE, PALO ALTO CA 94304
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang officer: EVP, R&D, Chief Medical Off. C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joshua A Kazam director 689 5TH AVENUE, 12TH FLOOR, NEW YORK NY 10022
Arie Belldegrun director, officer: Chairman, President and CEO UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Margo R Roberts officer: Chief Scientific Officer 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Kite Pharma (Kite Pharma) Headlines

From GuruFocus

Mario Gabelli's Top 5 New Buys for the 3rd Quarter

By Sydnee Gatewood Sydnee Gatewood 11-03-2017

Multiple Companies Achieve Yearly Highs

By yifan900 yifan900 10-03-2017

Mario Gabelli Exits Kite Pharma, Trims Time Warner

By Tiziano Frateschi Tiziano Frateschi 02-07-2018

Andreas Halvorsen Nearly Quadruples Stake in Kite Pharma

By David Goodloe David Goodloe 10-06-2015